A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors.
about
The macrophage: a therapeutic target in HIV-1 infectionCurrent perspectives on HIV-1 antiretroviral drug resistanceHIV Drug Resistance: Problems and PerspectivesNovel approaches to inhibit HIV entryStructure and dynamics of the gp120 V3 loop that confers noncompetitive resistance in R5 HIV-1(JR-FL) to maravirocSHIV-162P3 infection of rhesus macaques given maraviroc gel vaginally does not involve resistant virusesMultiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development.The host interactome of influenza virus presents new potential targets for antiviral drugs.A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity.Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody.HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry.Resistance to the CCR5 inhibitor 5P12-RANTES requires a difficult evolution from CCR5 to CXCR4 coreceptor use.Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotypingDistinct molecular pathways to X4 tropism for a V3-truncated human immunodeficiency virus type 1 lead to differential coreceptor interactions and sensitivity to a CXCR4 antagonist.ADS-J1 inhibits HIV-1 entry by interacting with gp120 and does not block fusion-active gp41 core formation.Variation in the biological properties of HIV-1 R5 envelopes: implications of envelope structure, transmission and pathogenesis.HIV-1 antiretroviral resistance: scientific principles and clinical applicationsCell-type specific requirements for thiol/disulfide exchange during HIV-1 entry and infectionTransmembrane protein aptamers that inhibit CCR5 expression and HIV coreceptor functionComparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C.Constitutively active CCR5 chemokine receptors differ in mediating HIV envelope-dependent fusion.Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages.Pharmacokinetics and pharmacodynamics of TBR-652, a novel CCR5 antagonist, in HIV-1-infected, antiretroviral treatment-experienced, CCR5 antagonist-naïve patients.Natural anti-CCR5 antibodies in HIV-infection and -exposureClinical use of CCR5 inhibitors in HIV and beyondCCR5: From Natural Resistance to a New Anti-HIV Strategy.Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaquesEvolution of coreceptor utilization to escape CCR5 antagonist therapy.Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5.Use of G-protein-coupled and -uncoupled CCR5 receptors by CCR5 inhibitor-resistant and -sensitive human immunodeficiency virus type 1 variants.A model of peptide triazole entry inhibitor binding to HIV-1 gp120 and the mechanism of bridging sheet disruptionGenotypic analysis of the V3 region of HIV from virologic nonresponders to maraviroc-containing regimens reveals distinct patterns of failure.Simultaneous zinc-finger nuclease editing of the HIV coreceptors ccr5 and cxcr4 protects CD4+ T cells from HIV-1 infection.Structure-function analysis of human immunodeficiency virus type 1 gp120 amino acid mutations associated with resistance to the CCR5 coreceptor antagonist vicriviroc.Vicriviroc, a new CC-chemokine receptor 5 inhibitor for treatment of HIV: properties, promises and challenges.Drug resistance in HIV-1.Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors.Modulatory effects of the CCR5 antagonist maraviroc on microglial pro-inflammatory activation elicited by gp120.A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5Cell therapies for treatment of human immunodeficiency virus infection.
P2860
Q26823236-961C7F5A-41F3-40C6-9206-29F520E12179Q26852626-46F5151B-1A5F-4007-B433-B253AA8BF984Q26864534-B2BB4132-0611-4201-A948-42A9B04497A8Q27013957-B74BC97C-477B-448B-9BB7-D8FE384ACFF2Q28534396-AAFF16CD-F798-4070-94E8-F37B18F6869EQ28742018-BB23FBF5-B384-429A-AA77-FC1B6DD15FFFQ30381745-FE206D1B-EEA9-4FF1-979B-3428443AE71DQ30405769-37D646C3-883A-498A-B6AC-F87B1EAB5BE7Q30654651-93CCD3F2-43A2-4419-9516-4C8975B23F20Q33798442-48C63602-A957-4094-B594-5E5B939D8492Q33807529-05842FF0-278E-443D-BB37-479FEBB44169Q33961704-6B7B1D8C-52E2-41F0-BC88-5037437D9B52Q34008448-011A9758-3898-49D8-9E81-254057FC2B25Q34055508-DC7CB7D3-92C8-4B34-9E48-F77440BAB312Q34151017-FBA89EF1-5BFB-445A-A170-E9099820E345Q34170655-72CC9E25-C7D9-4542-9926-F16E2E865F35Q34280466-19384E12-5E53-4F1E-A477-42726597B9BFQ34315133-0601F098-CBF9-4844-942E-14C308D6824BQ34343448-9C0FD8FB-FFE6-4FE6-A27E-55EAAEDD65E4Q34489239-76174318-A270-42FC-BB13-61EDB47739A7Q34565057-E8DA9B94-1269-4B66-AB98-FE847CCF83CAQ34846620-88D43C9F-DCD3-4433-A2A2-A8465E76177BQ35004830-2ACCBE45-7788-4865-908B-E1AF7442909FQ35018133-42B02B6A-3CF5-4C06-A0FC-F69B46F2571DQ35018145-628F3EAC-6923-43A5-8ED6-CEB19DDE9DC1Q35260605-9140133D-E031-4A7E-8033-FF374DCDB091Q35941408-A6E54DC5-6E2D-4131-A035-382C9F9A4D07Q36003168-80322758-2E51-4EB3-8342-2E05A93CE93FQ36607127-CC632E20-2225-42CE-BBFA-D46695C69818Q36911645-AEA7F1AF-CF33-4254-AE19-2273B04CF72FQ37238636-100780C7-C068-4B6B-941D-D3F52517C31AQ37335890-E3260C36-C59B-4237-AE5E-F515C0A1D5C4Q37429714-F9A8B077-9CD9-41CC-85E9-B52F7C4FCA02Q37452124-C9220579-F750-42F3-A601-1F0707EC26E5Q37780220-D7BFFCF9-316E-44ED-8472-5FE608E00534Q37967710-20EDBF8A-90AD-4243-8A39-0464B444F1CDQ38076139-EAB67F35-70A6-467B-9EAB-DB6132E6D5ECQ38330960-166183DF-1666-4AFF-9EC8-257FC4740B0AQ38341741-34A3586D-D64A-49F5-A705-B7FC9093A79DQ38366376-E03787CE-B24D-4F34-ABBF-D85F9BBA4E17
P2860
A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մարտին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors.
@ast
A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors.
@en
A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors.
@nl
type
label
A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors.
@ast
A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors.
@en
A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors.
@nl
prefLabel
A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors.
@ast
A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors.
@en
A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors.
@nl
P2860
P1476
A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors.
@en
P2093
Daniel R Kuritzkes
John P Moore
P2860
P304
P356
10.1097/COH.0B013E3283223D46
P577
2009-03-01T00:00:00Z